FRUZAQLA® (fruquintinib) efficacy
Consistent efficacy proven across 2 robust clinical trials.1-3
Beyond a single study, the FRUZAQLA clinical profile was established across 2 phase 3 trials. FRESCO and FRESCO-2, involving more than 1,100 patients, demonstrated consistent efficacy and a well-established safety profile.1-3 Overall survival was the primary endpoint in both trials, with additional measures including progression-free survival, objective response rate, disease control rate, duration of response, and safety.1,3 Patients were randomized (2:1) to receive FRUZAQLA 5 mg orally once daily for the first 21 days of each 28-day cycle plus BSC or placebo + BSC.1
Check out the results from FRESCO and FRESCO-2.
BSC=best supportive care.
FRUZAQLA patient profiles
Learn about patient types and why they may benefit from FRUZAQLA.
Established safety profile
Discover the safety profile of FRUZAQLA from the FRESCO and FRESCO-2 clinical trials.